Mumbai, Baltimore,UK, Japan,February 23,2022:Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities for Global Corporate Development as President, Corporate Development and Growth Markets. Dr. Egros takes over the Corporate Development role from Alan Butcherdeparting from the Company on February 28, 2022.   Dr. Egros will lead the development and execution of the Company’s inorganic growth strategy, including mergers and acquisitions, business development, in-licensing arrangements, and related matters. He will continue to lead business inLATAM and Asia regions in this new role.

“We are very pleased to announce Fabrice taking over responsibilities for Corporate Development in addition to the Growth Markets business. With Fabrice’s leadership anddemonstrated success in growing Lupin’s business through both organic and inorganic initiatives, we are well positioned to deliver on our growth aspirations.  We thank Alan for his contribution to our organization and wish him well for the future,” said Vinita Gupta, CEO, Lupin.

For the pastover six years, Dr. Egros has played an integral role in Lupin, leading businesses across both Growth and Developed markets. His extensive cross-border experience as well as successful experience with acquisitions, divestitures, joint ventures and partnerships will be an asset to Lupin in this new role.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue in research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: https://twitter.com/LupinGlobal|LinkedIn:https://www.linkedin.com/company/lupin

Facebook: http://www.facebook.com/LupinWorld/

Contact for media inquiries:

 Shweta Munjal

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com

Naini Thakkar

Email: nainithakkar@lupin.com